

Cerecin Expands Leadership Team with Appointment of Chief Medical Officer and Chief Operating Officer

Singapore and Denver, CO, September 01 2024 Cerecin Inc., a clinical-stage biotechnology company pioneering innovative neurotherapeutics, is pleased to announce the appointment of two key executives. These strategic additions to the leadership team reflect Cerecin's dedication to advancing transformative treatments for central nervous system (CNS) disorders.

Dr. Lars Nelleman Appointed as Chief Medical Officer

Cerecin is proud to welcome Dr. Lars Nelleman as Chief Medical Officer. With over 35 years of experience in the pharmaceutical industry, Dr. Nelleman is a respected figure in CNS therapeutics. His distinguished career has included senior leadership roles at prominent global pharmaceutical companies like Novo Nordisk and Lundbeck, where he contributed to the development and approval of numerous pharmaceuticals, mostly within CNS disorders.

At Lundbeck, Dr. Nelleman played a significant role in clinical development in a range of drugs for neurological and psychiatric disorders including neurodegenerative disorders like Alzheimer's and Parkinson's disease. Under his leadership expertise, he oversees clinical and medical development across Asia Pacific and established the region as an important hub for global clinical trials.

With a career deeply rooted in neuroscience, Dr. Nelleman's experience spans all phases of drug development, from early-stage development to regulatory approvals. At Cerecin, Dr. Nelleman's comprehensive expertise will be vital as the company accelerates its brain health pipeline, focusing on innovative therapies for conditions like Alzheimer's disease, migraine, and epilepsy.

Dr. Nelleman received his medical degree from Copenhagen University and has published articles on medicine and clinical research. His appointment strengthens Cerecin's medical leadership and underscores the company's commitment to advancing groundbreaking brain health solutions.

Lilian Chow Appointed as Chief Operating Officer

Cerecin is also pleased to announce the promotion of Lilian Chow to Chief Operating Officer. Lilian has made significant contributions to the company as Vice President of Clinical Operations and Regulatory Affairs, where she played a central role in advancing Cerecin's clinical programs targeting CNS disorders such as migraine, Alzheimer's disease, and infantile spasms, always working closely with cross-functional teams to ensure successful outcomes.

With 25 years of experience in clinical research, drug development, and regulatory strategy, Lilian has played an important role in shaping and executing Cerecin's global clinical development strategy. Lilian's operational acumen, coupled with her in-depth understanding of the CNS therapeutic landscape during her years in Lundbeck, has positioned Cerecin at the forefront of innovation in brain health.

A registered pharmacist, Lilian holds a Bachelor of Science (Pharmacy) with Honours from the National University of Singapore and a Master's degree in Management in Research & Development from Queensland University of Technology, Australia.

As COO, she will oversee all aspects of Cerecin's operational and clinical strategies, ensuring the successful execution of its development programs

Cerecin's Commitment to CNS Therapeutics

The appointments of Dr. Lars Nelleman as Chief Medical Officer and Lilian Chow as Chief Operating Officer come at a crucial time for Cerecin, as the company advances its portfolio of innovative therapies addressing critical CNS conditions. These leadership changes underscore Cerecin's commitment to scientific excellence, operational growth, and its mission to deliver transformative brain health solutions.

About Cerecin

Cerecin is a clinical-stage biotechnology company focused on developing drugs that target the metabolic bases of central nervous system diseases. Cerecin's development program leverages its extensive experience in neurology drug development and lipid science. Cerecin is supported by two multinational partners, Nestlé S.A. (NSRGY), and Wilmar International Limited (F34.SI). By bringing together the deep expertise of its leadership team and a highly differentiated drug development program, Cerecin is becoming a global leader in neurology therapeutics.

For more information visit www.cerecin.com, follow us on LinkedIn

Contact: pr@cerecin.com ©2024 Cerecin